New hope for endometrial cancer: Mo-Rez drug faces chemo in major trial

NCT ID NCT07286331

Recruiting now Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 16, 2026 · Updated 4 times

Summary

This large Phase 3 study tests a new drug called mocertatug rezetecan (Mo-Rez) against standard chemotherapy for people with endometrial cancer that has progressed after platinum-based chemo and immunotherapy. About 600 participants will be randomly assigned to receive either Mo-Rez or one of two standard chemo drugs (paclitaxel or doxorubicin). The main goals are to see if Mo-Rez shrinks tumors better and delays cancer growth compared to standard care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: mocertatug rezetecan (Mo-Rez)
What this could lead to: If it works, this could offer a new treatment option for endometrial cancer that has stopped responding to platinum chemo and immunotherapy.
What could go wrong: This is an early-stage Phase 3 trial, so results are not yet known. The new drug may not work better than standard chemo and could have unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endometrial carcinoma endometrium neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEOPLASMS, ENDOMETRIAL

Contacts and locations

Locations

GSK Investigational Site
RECRUITING

Buenos Aires, Argentina
GSK Investigational Site
RECRUITING

Ciudad Autonoma de Buenos Aire, C1012AAR, Argentina
GSK Investigational Site
RECRUITING

Ciudad Autonoma de Buenos Aire, C1426AGE, Argentina
GSK Investigational Site
RECRUITING

Rosario, S2000ORE, Argentina
GSK Investigational Site
RECRUITING

Auchenflower, Queensland, 4066, Australia
GSK Investigational Site
RECRUITING

Montreal, Quebec, H2X 0C1, Canada
GSK Investigational Site
RECRUITING

Montreal, Quebec, H4A 3J1, Canada
GSK Investigational Site
RECRUITING

Hokkaido, 060-8648, Japan
GSK Investigational Site
RECRUITING

Hyōgo, 673-8558, Japan
GSK Investigational Site
RECRUITING

Kanagawa, 216-8511, Japan
GSK Investigational Site
RECRUITING

Kyoto, 612-8555, Japan
GSK Investigational Site
RECRUITING

Mie, 514-8507, Japan
GSK Investigational Site
RECRUITING

Numakunai, 028-3695, Japan
GSK Investigational Site
RECRUITING

Okinawa, 901-2725, Japan
GSK Investigational Site
RECRUITING

Saitama, 350-1298, Japan
GSK Investigational Site
RECRUITING

Panama City, Panama
GSK Investigational Site
RECRUITING

Panama City, Panama
GSK Investigational Site
RECRUITING

Panama City, Panama

More trials for these conditions

Other studies related to the condition(s) this trial covers.